The revamped and “more anti-vax skewed ACIP committee” at the CDC “has a bone to pick with mRNA vaccines,” according to ...

Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS Newswire / June 12, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the ...

The FDA expanded its approval of Moderna's RSV vaccine on Thursday to include adults under age 60 at increased risk of the disease.

The U.S. Food and Drug Administration (FDA) has added new warnings to the Pfizer and Moderna COVID-19 vaccines about a rare ...

This builds upon its initial approval in May 2024 for adults aged 60 years and older, which makes mRESVIA the second approved ...

Moderna's shares fell 2.3% on Friday on concerns about whether a new CDC advisory panel would back the use of the company's ...

We came across a bullish thesis on Moderna, Inc. (MRNA) on Natan’s Substack. In this article, we will summarize the bulls’ ...

The FDA has updated labels on the top two COVID-19 vaccines to warn of a rare heart side effect, mostly seen in young men.

Moderna (MRNA) ended the recent trading session at $25.90, demonstrating a +1.97% change from the preceding day's closing price. This change outpaced the S&P 500's 0.22% loss on the day. Elsewhere ...

Dr. Todd Ellerin, Vice Chair of Department of Medicine of South Shore Health discusses the new FDA warning regarding Pfizer and Moderna COVID-19 vaccines. The FDA is expanding warnings on Pfizer and ...

The U.S. approved a new COVID-19 vaccine made by Moderna late Friday but with limits on who can use it — not a replacement for the company's existing shot, but a second option. The new vaccine ...

U.S. health officials have expanded warnings about a rare heart side effect associated with the two leading COVID-19 vaccines ...